In this cohort study of patients with cirrhosis who were receiving furosemide and spironolactone, SGLT-2 inhibitor use was associated with a lower risk of serious liver events, defined as incidence of ascites, variceal development, hyponatremia, or all-cause mortality. This evidence concerns the gene SLC5A2 and Hyponatremia.